Efficacy

Lumakras (sotorasib) Efficacy in Lung Cancer

Lumakras, also known by its generic name sotorasib, is a medication specifically approved for the treatment of non-small cell lung cancer (NSCLC) with a particular genetic mutation known as KRAS G12C. This mutation is present in a subset of patients with NSCLC and has historically been considered challenging to target with therapy. The efficacy of Lumakras in lung cancer was demonstrated in a phase 2 clinical trial, known as CodeBreaK 100, which showed that sotorasib provided a significant benefit in terms of tumor shrinkage and disease control in patients with the KRAS G12C mutation who had previously undergone treatment with chemotherapy and/or immunotherapy.

In the trial, Lumakras achieved an objective response rate (ORR) of approximately 36%, with a median duration of response lasting 10 months. This indicated that the drug could effectively induce tumor regression in a significant proportion of patients. Additionally, the disease control rate (DCR) was reported to be around 81%, suggesting that most patients experienced either tumor shrinkage or stabilization of their disease. The median progression-free survival (PFS) was approximately 6.8 months, providing evidence of Lumakras's ability to delay disease progression in this patient population.

Krazati (adagrasib) Efficacy in Lung Cancer

Krazati, with the generic name adagrasib, is another targeted therapy for NSCLC patients harboring the KRAS G12C mutation. While adagrasib has shown promise in early clinical trials, as of the knowledge cutoff date, it has not yet received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer. However, preliminary data from ongoing clinical trials suggest that adagrasib may have a similar efficacy profile to sotorasib, with the potential to provide clinical benefit to patients with this specific genetic alteration.

In early clinical trial results, adagrasib demonstrated an ORR comparable to that of sotorasib, with a substantial number of patients experiencing tumor shrinkage. The DCR for adagrasib was also high, indicating that the majority of patients achieved disease stabilization or better. The PFS data, while still maturing, suggests that adagrasib has the potential to be an effective treatment option for patients with KRAS G12C-mutated NSCLC. Further studies and ongoing clinical trials are necessary to fully establish the efficacy and safety profile of adagrasib for the treatment of lung cancer.